TY - JOUR T1 - Community-associated methicillin-resistant <em>Staphylococcus aureus</em> infection JF - Canadian Family Physician JO - Can Fam Physician SP - 512 LP - 520 VL - 63 IS - 7 AU - Kassandra Loewen AU - Yoko Schreiber AU - Mike Kirlew AU - Natalie Bocking AU - Len Kelly Y1 - 2017/07/01 UR - http://www.cfp.ca/content/63/7/512.abstract N2 - Objective To provide information on the prevalence and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections and the distinction between community-associated MRSA and health care–associated MRSA.Quality of evidence The MEDLINE and EMBASE databases were searched from 2005 to 2016. Epidemiologic studies were summarized and the relevant treatment literature was based on level I evidence.Main message The incidence of community-associated MRSA infection is rising. Certain populations, including indigenous Canadians and homeless populations, are particularly affected. Community-associated MRSA can be distinguished from health care–associated MRSA based on genetic, epidemiologic, or microbiological profiles. It retains susceptibility to some oral agents including trimethoprim-sulfamethoxazole, clindamycin, and tetracyclines. Community-associated MRSA typically presents as purulent skin and soft tissue infection, but invasive infection occurs and can lead to severe, complicated disease. Treatment choices and the need for empiric MRSA coverage are influenced by the type and severity of infection.Conclusion Community-associated MRSA is a common cause of skin and soft tissue infections and might be common in populations where overcrowding and limited access to clean water exist. ER -